

**OBJ** LIMITED

---

**OCTOBER 2016 AGM**

**PROVIDING INNOVATIVE SOLUTIONS TO THE PHARMACEUTICAL, COSMETIC, SKINCARE,  
& CONSUMER PRODUCTS INDUSTRIES**

This Presentation has been prepared by OBJ Limited (ABN 72 056 482 636) (OBJ or the Company). This Presentation contains summary information about OBJ and its activities current as at the date of this Presentation. The information in this Presentation is of general background and does not purport to be complete or to comprise all the information that a shareholder or potential investor in OBJ may require in order to determine whether to deal in OBJ shares. It should be read in conjunction with OBJ's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), which are available at [www.asx.com.au](http://www.asx.com.au). This document is not a prospectus or a product disclosure statement under the Corporations Act (Cth) 2001 (Corporations Act) and has not been lodged with the Australian Securities and Investments Commission (ASIC).

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This Presentation contains certain “forward-looking statements”. The words “expect”, “should”, “could”, “may”, “will”, “predict”, “plan”, “scenario”, “forecasts”, “anticipates”, “outlook” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Such forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with the Company and the industry (including those set out below) which may affect the accuracy of the forward-looking statements. The Company does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this presentation, or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

This document may not be released or distributed in the United States. This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. Securities in the Company have not been, and will not be, registered under the U.S. Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States unless the securities are registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration. To the maximum extent permitted by law, OBJ and its respective advisers and affiliates, directors, officers and employees make no representation or warranty, express or implied, as to the accuracy, reliability or completeness of information in the Presentation.

# OVERVIEW

- Life sciences company focused on product performance enhancement through physical rather than chemical means.
- Executed new Product Development Agreement with Procter & Gamble (P&G) that extends to 2021.
- The Eye Wand for Olay & SKII now launched in China with other countries to follow.
- Licensing Term Sheet for second Licensed product (Wave II) committed and launch planned 2017
- Wave III, Wave IV Wave V and Wave VI in late stage development.
- Master License Agreement (MLA) executed, covering all products to be licensed to P&G.
- Bodyguard – major clinical trial & consumer research study completed with outstanding results – manufacturing research & discussions with four potential distributors maturing.
- Studies for surface hygiene reconfirmed 300% increase in the kill rate of Golden Staph. Laboratory testing by two major potential partners underway
- Revenues from Wave 1 (Olay & SK-II) commencing December 2016 & Wave II June 2017.

# THE SCIENCE OF DIAMAGNETIC REPULSION



Driving performance through physical rather  
than chemical science.

# PARTNERING

PROCTER & GAMBLE (P&G) IS THE WORLD'S LARGEST FMCG COMPANY

- 80 million product sales per day
- Largest number of billion dollar brands
- Revenues of \$US76bn/annum



New PDA executed covering all P&G product developments out to 2021.



Wave I Licensed and in-market, Wave II Licensing Term Sheet committed with an additional four new products in advanced development stages.



The Eye Wand, initially launched by SK-II in late 2014 across five countries, resulted in excellent consumer reaction – now being distributed throughout China & soon to other countries.




Advanced negotiations regarding the expansion of the PDA to accommodate additional OBJ technologies.



# INTERNAL PRODUCT DEVELOPMENTS

## BODYGUARD

WORLD'S FIRST PRODUCT RANGE ENGINEERED  
TO REVERSE THE EFFECT OF JOINT AGEING



Clinical trial highly successful – results being shared with four potential licensees.

Market sectors now defined as:


- Healthy aging
- Connective tissues
- VMS
- TCM

Recent development of hydro-gels – will greatly facilitate not only the manufacturing but also clinical efficacy.

Development work commenced on the Hot Dot.

Discussions well advanced for distribution with four major FMCG & pharmaceutical companies.

# BODYGUARD CLINICAL TRIAL RESULT



Now established that Bodyguard ingredients, with their extensive safety profile & over-the-counter regulatory status, provided superior long-term restoration & maintenance of joint health compared to current prescription & high risk non-steroidal, anti-inflammatory drugs.


Now established that Bodyguard can potentially aid in preserving joint lubrication & energy absorption that translates into superior restoration of function & greater joint pain reduction than current analgesics.

Now established that OBJ's technology platforms have increased the efficacy of a wide range of therapeutic agents including vitamins, minerals, electrolytes & supplements that are significantly limited by normal first pass metabolism. Discussions well advanced with Reckitt Benckiser, Pfizer, P&G & Beiersdorf for distribution of the Bodyguard range.

Product design now maturing for Kneeguard – other joint treatments commencing.

# Bodyguard Market Segments


Vertical and Horizontal **partnering opportunities**





# Bodyguard Life Sciences

*The Musculoskeletal Disorder OTC remedy category is a USD\$50 B market which will grow by 50% over next 5 years – fuelled by emerging middle class markets and new product innovation.*



# NEW INTERNAL PRODUCT DEVELOPMENTS

## ADVANCED PACKAGING



By incorporating new technologies directly into packaging forms, OBJ provides partners with the ability to rapidly innovate new consumer focused product forms without the need for altered chemistry or regulatory approvals.

## CONFIGURABLE EMULSION



OBJ's new Dynamically Configurable Emulsion (DCE) technology, the world's first technology to manipulate the structure & performance of emulsions during application to the skin, is an example of this initiative & is under negotiation with two potential partners.

## NEW TECHNOLOGIES



A range of new innovations in skin diagnostics & at home/work treatments for consumer use. Discussions are underway with the first targeted partnering companies & when commercialised, will be an attractive ancillary to the Company's existing technologies.

# INTERNAL PRODUCT DEVELOPMENTS



## SURFACE HYGIENE PROGRAM

- Surface disinfection is a global hygiene concern as bacteria become resistant to current disinfectants. OBJ surface hygiene technology has demonstrated a 300% increase in the kill rate of Golden Staph bacteria in University studies.
- Two major manufacturers of disinfectants & cleaners are evaluating OBJ's technology for enhanced performance with their formulations.
- Surface hygiene presents minimal regulatory barriers & potentially speedy access to market.
- By increasing the penetration of common disinfectants into the surfaces that dominate hospitals & homes, OBJ can potentially deliver significantly increased hygiene outcomes without the need for harsher or more toxic chemistry.
- A comprehensive testing program at UWA has confirmed the 300% increase in kill rates using OBJ microarray technology.

# INTERNAL PRODUCT DEVELOPMENTS



## PRE-SURGICAL PATCHES

- OBJ's surface disinfection technology can be applied to the field of pre-surgical skin hygiene & the growing hospital acquired infection industry.
- OBJ surface hygiene technology has been proven to enhance penetration of follicles & other structures that can harbor bacteria & infectious agents that traditional swabbing cannot reach.
- The hospital acquired infection industry is currently valued at US\$90bn.
- Initial proof of technical principal studies have now been completed & initial discussions with major international hygiene companies by Dr Steve Meller have been encouraging.
- An adhesive patch using the BodyGuard technology, & existing safe antiseptics, has the potential to change the way pre-surgical disinfection is managed.

# SUMMARY OF 2016 ACHIEVEMENTS

- Increase in the Company's market capitalisation
- PDA extended to 2021 & Master License Agreement executed with P&G.
- First licensed product (Wave I) now being distributed by P&G.
- Adoption of OBJ licensed products by two P&G brands.
- Second product license agreed with P&G, distribution to commence in 2017.
- Further four new P&G products under late stage development.
- Successful Bodyguard clinical trial completed at UQ.
- Multiple potential distributors evaluating Bodyguard with one having completed technical due diligence.
- New surface hygiene technology being evaluated by two of the world's largest hygiene companies in their laboratories.
- Multiple microarray patents granted in key commercial markets.
- Revenues expected to commence for Wave I relaunch (from Dec 2016) & Wave II (from June 2017)

For more information visit: [www.obj.com.au](http://www.obj.com.au)



Contact:  
Matt Wright  
NWR Communications  
+61 451 896 420  
[matt@nwrcommunications.com](mailto:matt@nwrcommunications.com)